Indaptus Therapeutics (INDP) reported Thursday new data from an ongoing phase 1 trial of Decoy20, which validated Decoy20's ability to modulate a patient's immune system in a "controlled and potentially meaningful way."
The biotechnology company said weekly treatment with Decoy20 led to broad immune cell trafficking that is a key pharmacodynamic marker, which is "critical for successful anti-tumor therapy," Indaptus Chief Scientific Officer Michael Newman said.
INDP shares were 3% lower in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。